Chemistry:CP 42,096
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C26H34O4 |
| Molar mass | 410.554 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
CP 42,096 is an analgesic drug which acts as a cannabinoid agonist. It was developed by Pfizer in the 1980s as part of the research that led to the development of levonantradol,[1][2][3] and is more potent than THC but less potent than newer compounds such as CP 55,244.[4][5]
See also
References
- ↑ "Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model". Molecular Pharmacology 33 (3): 297–302. March 1988. PMID 3352594.
- ↑ "The evaluation of synthetic cannabimimetic congeners for discriminative stimulus and cataleptogenic effects in rats". NIDA Research Monograph 105: 421. 1990. OCLC 7457082. PMID 1652087.
- ↑ "Levonantradol". Marihuana and Medicine.. Totowa, NJ: Humana Press. 1999. pp. 553–560. doi:10.1007/978-1-59259-710-9_53. ISBN 978-1-4757-5717-0.
- ↑ "Enhancement of brain [3H]flunitrazepam binding and analgesic activity of synthetic cannabimimetics". European Journal of Pharmacology 109 (2): 201–12. February 1985. doi:10.1016/0014-2999(85)90421-2. PMID 2986995.
- ↑ "Hexahydrocannabinol (HHC) and related substances.". European Monitoring Centre for Drugs and Drug Addiction. 2023. https://www.emcdda.europa.eu/system/files/documents/2023-05/emcdda-technical-report-hhc-and-related-substances.pdf.
 |  |
